BioCryst Pharmaceuticals, Inc.
4505 Emperor Blvd.
Durham, NC 27703
United States
Tel: 919-859-1302
524 articles with BioCryst Pharmaceuticals, Inc.
-
BioCryst Announces ORLADEYO® (berotralstat) Data to be Presented at European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress 2022
6/22/2022
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced multiple upcoming data presentations at the European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress 2022 from July 1-3, 2022, at the O2 universum in Prague, Czech Republic.
-
BioCryst Selects Pint Pharma as Commercial Partner for ORLADEYO® (berotralstat) in Latin America
6/9/2022
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the company has entered into an exclusive collaboration with Pint Pharma GmbH to register and promote ORLADEYO® (berotralstat) in the pan-Latin America (LATAM) region.
-
FDA Grants Fast Track Designation for BioCryst’s ALK-2 Inhibitor, BCX9250
6/8/2022
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for BCX9250 for the prevention of heterotopic ossification (HO) in patients with fibrodysplasia ossificans progressiva (FOP).
-
BioCryst Announces Approval of ORLADEYO® (berotralstat) by Swissmedic
6/7/2022
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that Swissmedic has granted marketing authorization for oral, once-daily ORLADEYO® (berotralstat) for the routine prevention of recurrent hereditary angioedema (HAE) attacks in patients 12 years and older in Switzerland.
-
BioCryst Announces Health Canada has Authorized ORLADEYO® (berotralstat), the Only Oral Treatment for the Prevention of Hereditary Angioedema Attacks
6/6/2022
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that Health Canada has approved oral, once-daily ORLADEYO® (berotralstat) for the routine prevention of recurrent hereditary angioedema (HAE) attacks in patients 12 years and older.
-
BioCryst to Present at Upcoming Investor Conferences - June 01, 2022
6/1/2022
BioCryst Pharmaceuticals, Inc. announced that the company will present at the Jefferies Healthcare Conference in New York, NY on Wednesday, June 8, 2022, at 9:00 a.m. ET and the JMP Securities Life Sciences Conference in New York, NY on Wednesday, June 15, 2022, at 12:00 p.m. ET.
-
Pfizer's Paxlovid racks up a rare trial miss, Medicago and GSK publish positive data for their plant-based particle vaccine and Rhythm Pharmaceuticals touts strong potential in Bardet-Biedl Syndrome.
-
BioCryst to Present at Upcoming Investor Conferences - May 06, 2022
5/6/2022
BioCryst Pharmaceuticals, Inc. announced that the company will present at the following conferences:.
-
BioCryst's success of its Orladeyo launch in its Q1 report was overshadowed by the news that the FDA had placed a partial clinical hold on three of its clinical trials evaluating BCX9930
-
BioCryst Reports First Quarter 2022 Financial Results and Upcoming Key Milestones
5/5/2022
BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today reported financial results for the first quarter ended March 31, 2022, and provided a corporate update.
-
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 04, 2022
5/4/2022
BioCryst Pharmaceuticals, Inc. announced that the compensation committee of BioCryst’s board of directors granted 23 newly-hired employees stock options to purchase an aggregate of 138,100 shares, and restricted stock units covering an aggregate of 69,050 shares, of BioCryst common stock.
-
European Medicines Agency Grants PRIME Designation to BioCryst’s ALK-2 Inhibitor, BCX9250, for Treatment of Fibrodysplasia Ossificans ProgressivaBCX9250 is first investigational drug for FOP to be eligible for program
4/27/2022
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the European Medicines Agency (EMA) has granted access to the Priority Medicines (PRIME) scheme for BCX9250, a novel, oral activin receptor-like kinase-2 (ALK-2) inhibitor discovered and developed by BioCryst for the treatment of fibrodysplasia ossificans progressiva (FOP).
-
BioCryst to Report First Quarter 2022 Financial Results on May 5
4/21/2022
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its first quarter 2022 financial results Thursday, May 5, 2022.
-
The trial demonstrated a safety profile in the younger age group as seen in patients 12 and older, with no severe side effects and no one dropping out from adverse events.
-
BioCryst to Present at Upcoming Investor Conference
4/11/2022
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the 21st Annual Needham Virtual Healthcare Conference on Thursday, April 14, 2022, at 11:45 a.m. ET.
-
BioCryst Pauses Enrollment in BCX9930 Clinical Trials
4/8/2022
BioCryst Pharmaceuticals, Inc. announced that the company has paused enrollment in clinical trials with BCX9930 while the company investigates elevated serum creatinine levels seen in some patients.
-
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Apr 05, 2022
4/5/2022
BioCryst Pharmaceuticals, Inc. announced that the compensation committee of BioCryst’s board of directors granted 19 newly-hired employees stock options to purchase an aggregate of 124,800 shares, and restricted stock units covering an aggregate of 47,400 shares, of BioCryst common stock.
-
BioCryst to Present at Upcoming Investor Conferences in March 2022
3/3/2022
BioCryst Pharmaceuticals, Inc. announced that the company will present at the Cowen 42nd Annual Health Care Conference on Wednesday, March 9, 2022, at 9:50 a.m. ET.
-
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Mar 02, 2022
3/2/2022
BioCryst Pharmaceuticals, Inc. announced that the compensation committee of BioCryst’s board of directors granted 17 newly-hired employees stock options to purchase an aggregate of 228,000 shares, and restricted stock units covering an aggregate of 62,000 shares, of BioCryst common stock.
-
BioCryst Presents New Data Demonstrating Sustained Reductions in Attack Rates and Improvement in Quality of Life Among HAE Patients Following Long-Term Treatment with ORLADEYO® (berotralstat)
2/24/2022
BioCryst Pharmaceuticals, Inc. announced new long-term efficacy and safety data from the APeX-2 clinical trial evaluating oral, once-daily ORLADEYO® for the prophylactic treatment of hereditary angioedema showing sustained reductions in attack rates and improvement in quality of life among patients living with HAE, regardless of their baseline attack rates and initial responses to ORLADEYO.